MENU

ImvivaBio CTA313: Dual CD19/BCMA CAR-T Data for Lupus (2026)

Yahoo Finance USA
Overview
ImvivaBio presented 12-month follow-up data for CTA313, an allogeneic dual-targeted CD19/BCMA CAR-T therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The therapy achieved an 88% DORIS remission rate at Month 12 in refractory SLE patients and demonstrated a superior immune reset compared to single-target CD19 approaches. These results support the transition to a global Phase 1b ALLNEW basket study.
In Depth

Key Findings

CTA313 demonstrated durable remission and immune reconstitution in patients with refractory SLE. In a pooled analysis of 14 heavily pretreated patients with minimal renal involvement, the Definition of Remission in SLE (DORIS) remission rate reached 73% at Month 6 and 88% (7/8 patients) at Month 12. Furthermore, 92.9% of these patients were off immunosuppressants at the data cutoff, and 92% of evaluable patients were taking glucocorticoids at 5 mg/day or less by Month 6.

Technical Details

CTA313 is an “off-the-shelf” allogeneic CAR-T therapy targeting both CD19 and B-cell maturation antigen (BCMA). This dual-targeting approach aims to eliminate both autoreactive B-cell precursors and plasma-cell reservoirs to prevent relapse. Technical data indicates:

  • B-cell Dynamics: Median B cells dropped from 52.2 to 0 cells/µL by Day 7, with reconstitution around Day 42 consisting of more than 95% naive B cells.
  • Biomarkers: Anti-dsDNA antibodies became undetectable by Month 3 and remained so for up to one year; complement component C3 rose from 0.65 to 1.34 g/L by Day 28.
  • Comparative Efficacy: In SLE with minimal renal involvement, the dual-target approach achieved a 12-month DORIS remission rate of 80%, compared to 20% for single-target CD19 CAR-T (n=17 for single vs n=27 for dual).
  • Safety: Cytokine release syndrome (CRS) occurred in 35.7% of patients (all Grade 1). Grade 3 or higher adverse events included neutropenia (71.4%), thrombocytopenia (21.4%), and infections (21.4%). No neurotoxicity or graft-versus-host disease (GvHD) was observed.

Background and Context

Current standard-of-care for SLE and LN relies on broad immunosuppression, which often results in incomplete responses and recurrent flares. ImvivaBio’s approach utilizes an allogeneic “immune reset” mechanism, where single-cell analysis showed no overlap between pretreatment autoreactive clones and newly formed clones.

Significance and Outlook

The data suggests that dual CD19/BCMA targeting provides deeper B-cell eradication and superior remission outcomes than single-target therapies. These findings inform the design of the upcoming global Phase 1b ALLNEW basket study.

Source: https://finance.yahoo.com/healthcare/articles/imvivabio-presents-longer-term-data-130000771.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC